Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01060670 · ClinicalTrials.gov registry record · NA

A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers

A NA study, sponsored by Integra LifeSciences Corporation.

Completed
Registry status
NA
Development phase
545
Enrollment target

NCT01060670: Completed NA study, sponsored by Integra LifeSciences Corporation.

NCT01060670 is a NA study that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 545 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01060670, a NA study, has completed, sponsored by Integra LifeSciences Corporation.

COMPLETED
Registry status
NA
Development phase
545 participants
Enrollment target

Study Summary

The objective of this study is to evaluate the safety and efficacy of the INTEGRA® Dermal Regeneration Template for the treatment of diabetic foot ulcers located distal to the malleolus in subjects with diabetes mellitus, neuropathy, and without significantly compromised arterial circulation.

Primary Outcome

100% closure as assessed by the Investigator and confirmed at 2 consecutive treatment phase visits.

Interventions

  • DEVICE Integra® Dermal Regeneration Template
  • OTHER Conventional Wound Therapy

Trial Details

FieldValue
Enrollment Target 545 participants
Start Date 2010-04
Est. Completion 2014-06
Phase NA
Integra LifeSciences Corporation

60 total trials

What the finished NCT01060670 record still lists

NCT01060670 is an interventional study that assigns participants to a tested intervention. The registered 545 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (61% lower).

The record links to 0 conditions, and to 2 interventions - of which Integra® Dermal Regeneration Template is the first listed.

NCT01060670 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01060670 about?

NCT01060670 is a clinical study titled "A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers". The objective of this study is to evaluate the safety and efficacy of the INTEGRA® Dermal Regeneration Template for the treatment of diabetic foot ulcers located distal to the malleolus in subjects with diabetes mellitus, neuropathy, and without significantly compromised arterial circulation.

What is the current status of trial NCT01060670?

This trial is currently completed. It is a NA study. The enrollment target is 545 participants. The study started on 2010-04. Estimated completion is 2014-06.

What interventions are being tested in trial NCT01060670?

The interventions under investigation include: Integra® Dermal Regeneration Template (DEVICE), Conventional Wound Therapy (OTHER).

Who is sponsoring clinical trial NCT01060670?

This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01060670's enrollment target sits among peer trials

545 186th of 2000 higher than 1,815 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04553523 · 545 participants · NA

    Hydrus® Microstent New Enrollment Post-Approval Study

  • NCT03572374 · 546 participants · NA

    Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job

  • NCT05937685 · 546 participants · NA

    Reducing Blood Pressure in Patients With High Cardiovascular Risk

  • NCT06416150 · 546 participants · NA

    Reducing Urban Cervical Cancer Disparities

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01060670, the US trial registry maintained by the National Library of Medicine. NCT01060670 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.